Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep537 | Diabetes complications | ECE2017

PDE5i preserves renal function in models of Diabetic Nephropathy: from bench to bedside

Pofi Riccardo , Fiore Daniela , Feola Tiziana , Giannetta Elisa , Grazie Giulia Le , Dato Carla Di , Gianfrilli Daniele , Barbano Biagio , Venneri Mary A. , Lenzi Andrea , Isidori Andrea M.

One third of diabetic patients suffer from Diabetic Nephropathy (DN) that leads to end-stage renal disease (ESRD). The molecular pathways involved remain underexplored. We showed that chronic phosphodiesterase-5 inhibition (PDE5i) improve vascular inflammation [1] and tissue remodelling, reducing proteinuria [2] in murine diabetes. Our aim was to investigate the effect of PDE5i on animal and human models of DN.Materials and methods: 16 mice were randomly...

ea0075d24 | Diabetes | EYES2021

Sex-specific cardioprotection of daily tadalafil in patients with type-2 diabetes. The RECOGITO, randomized, double-blind, placebo-controlled trial

Pofi Riccardo , Giannetta Elisa , Feola Tiziana , Galea Nicola , Campolo Federica , Barbagallo Federica , Badagliacca Roberto , Barbano Biagio , Ciolina Federica , Defeudis Giuseppe , Filardi Tiziana , Sesti Franz , Minnetti Marianna , Dario Vizza Carmine , Pasqualetti Patrizio , Carbone Iacopo , Francone Marco , Catalano Carlo , Pozzilli Paolo , Lenzi Andrea , Venneri Mary Anna , Gianfrilli Daniele , Isidori Andrea M.

Background: Cyclic GMP-phosphodiesterase type 5(PDE5) inhibition was shown to counteract maladaptive cardiac changes triggered by diabetes in some, but not all studies.Objective: To assess sex differences in cardiac remodeling after PDE5 inhibition in patients with diabetic cardiomyopathy.Methods: 20-week, double-blind, randomized, placebo-controlled trial (NCT01803828). 220 men and women (45-80 years) with long-duration (>3 ye...